Cross-sectional study 69 Systemic Sclerosis Pts: 33% w/ PPI-refractory esophagitis & 2/3 w/ EGD normal esophageal mucosa. PPI-refractory esophagitis was more commonly linked to diffuse SSc subset (43 vs 17%) and GI dysmotility (66 vs 8%; p = <0.001) https://t.co/yIBlyNZacB https://t.co/dempwjX5XO

Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/YgtujQjNqI https://t.co/9uazZLuoRb

JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/TmAIHswwli https://t.co/MwdE7MhQKI

Moving Forward on RA Prevention Trials Now that multiple prevention clinical trials for rheumatoid arthritis (RA) have been completed, a group of investigators have reviewed the results and published their recommendations for future trial designs and drug development to assess… https://t.co/ppmWa27tgd https://t.co/lQEtBNRZRm

Visit the latest RheumNow Therapeutic Updates to learn more about earlier treatment with biologics to reduce the risk of organ damage in #Lupus #SponsoredbyGSKUSMA https://t.co/ZqWX0rlyfB https://t.co/IsDeUySaZd

Conservative Treatment of Acute Vertebral Fractures A network meta-analysis of pain outcomes in patients with acute osteoporotic vertebral compression fractures (VCFs) showed short-term success with calcitonin and NSAIDs in decreasing pain during activity, but long-term… https://t.co/uqQAoypdiV https://t.co/HNgKtzMs03

ACR Speaks Against Repeated Cuts to Medicare Reimbursements The ACR has submitted its comments to the CMS regarding the proposed CY 2025 Medicare Physician Fee Schedule and Quality Payment Program rule and its impact on rheums and rheum interprofessional team members’ ability to… https://t.co/cIjJwOWA5Z https://t.co/sPLZFUxywl

Study of 65 myositis pts w/ PM/Scl Abs found ILD as a dominant feature, esp. if double pos. w/ myositis-specific Abs (MSAs 52%). PM/Scl+ more likely women (90 vs 68%), w/ sclerodactyly (16 vs 0%). Double ++ had more ILD (91%) & mortality (21% vs 0) https://t.co/grz7NW410N https://t.co/pdDilBabdf

Systematic literature review IVIG in systemic sclerosis included 12 studies, 266 pts. A favorable effect was seen for skin thickening, MSK pain, GI Sxs, Steroid use, QOL. But less effect for pulmonary Dz, PFTs (stabilized?). Studies were not of high-quality… https://t.co/c3Xix9K2XK https://t.co/L3LKwegmkf

Guselkumab (Tremfy) receives U.S. FDA approval for adults with moderately to severely active ulcerative colitis, based on pivotal, Phase 2b/3 QUASAR study showing 50% remission at week 44 (vs 19 PBO) for those on GUS 200 mg q 4 wk https://t.co/kvtqXFUezw https://t.co/NrYi61yerm

JAMA: RCT in 101 chronic low back pain pts showed a single nondeceptive placebo injection reduced LBP intensity for 1 month https://t.co/RI9TnvmeMJ https://t.co/BF6UBqMXrD

Consensus Guidelines on Pediatric Methotrexate Use MTX is commonly used in the treatment of pediatric inflammatory skin conditions, often for off-label indications. Consensus based recommendations were published to address 5 major subjects: -indications and contraindications… https://t.co/6JtIMGOAhq https://t.co/OZJLqAyOnF